Kaposi sarcoma (KS) is a vascular neoplasm that often manifests with multiple vascular nodules on the skin and other organs. Various imaging modalities can be used to display disease extent. Herein we present a 65-year-old female patient with human immunodeficiency virus negative KS along with her whole-body positron emission tomography/computed tomography imaging findings. Keywords: Positron emission tomography/computed tomography, kaposi sarcoma, HIV
Introduction
Kaposi sarcoma (KS) is an immunodeficiency syndromerelated disease that has been reported to be strongly associated with human herpes virus-8 (1,2). The skin, mucosal surfaces and lung are the main sites of involvement. Visceral involvement predicts survival especially in patients with acquired immune deficiency syndrome (AIDS)-associated KS, thus accurate staging and identification of diseased sites with fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is useful in the management of these patients (3). Herein we present a patient with human immunodeficiency virus (HIV)-negative KS staged by 18 F-FDG PET/CT imaging.
Case Report
A 65-year-old female patient was referred to our hospital with complaints of swelling and nodular skin lesions on both legs. She had a history of rheumatoid arthritis and treatment with corticosteroid medication for five years. On physical examination, dark blue-purplish macular and nodular skin lesions were observed on the legs along with pretibial edema (Figure 1 ). The lesions that had appeared within a few months were not painful. She was diagnosed with KS with biopsy of the skin lesions ( Figure  2 ). Laboratory tests were within normal limits except an elevated erythrocyte sedimentation rate. Anti-HIV antibody was negative. She was referred to our department for initial staging with 18 F-FDG PET/CT imaging. A whole body 18 F-FDG PET/CT imaging was performed 60 minutes after 370 megabequerel 18 F-FDG injection using an integrated PET/CT scanner (Siemens, Biograph mCT, Germany). 18 F-FDG PET/CT imaging showed multiple nodular skin lesions with increased FDG uptake on both legs (SUV max : 6.1). In addition, there were hypermetabolic bilateral inguinal and popliteal lymph nodes (SUV max : 3.6-5.6) ( Figure 3 ).
Literature Review and Discussion
KS is a common tumor in AIDS patients. Most patients present with a single or few lesions, however multiple lesions have also been reported (4). In most cases, the lesions are asymptomatic. peribronchial and perivascular opacities is characteristic on high resolution CT. MRI has higher sensitivity in detecting cardiac lesions and bone involvement (6, 7) . Thallium-201 ( 201 Tl) and gallium-67 ( 67 Ga) scintigraphy had been previously used for differential diagnosis. 67 Ga negative and 201 Tl positive lesions were most likely accepted as KS, whereas both 67 Ga and 201 Tl positive lesions were considered as lymphoma (8) . 99m Tc tetrofosmin had also been once used in patients with KS as a tumor screening agent (9) . Recently, 18 F-FDG PET/CT imaging is being used for the evaluation of visceral and lymphatic involvement, and staging of KS. It has a role in both staging and the evaluation of response to therapy (10, 11) . In addition, PET/CT is an effective method in detecting clinically occult KS lesions that were not detected with other imaging methods (12) . KS may demonstrate heterogeneous FDG avidity. In some previous studies, lymph node and visceral involvement such as the bone and lungs were detected by 18 F-FDG PET/CT imaging (10, 11, 13, 14) . Diffuse and focal FDG uptake in the skin have also been reported (14, 15) . In our patient, an increased FDG uptake was detected in nodular skin lesions on the lower extremities, and the highest SUV max value of these lesions was 6.1. 18 F-FDG PET/CT imaging detected lymph node involvement in addition to widespread cutaneous involvement in our patient. In conclusion, whole body 18 F-FDG PET/CT imaging can detect the extent of visceral and lymphatic involvement, and makes a significant contribution in both staging and clinical management of KS. 
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